Inactive Ingredient Search for Approved Drug Products
You are Searching: Change and Deletion by Inactive Ingredient Name Beginning with G
| Quarter | Inactive Ingredient | Route of Administration | Dosage Form | Maximum Potency per unit dose | Maximum Daily Exposure | Status | |
|---|---|---|---|---|---|---|---|
| Q1 2024 | GLYCERYL MONO AND DICAPRYLOCAPRATE | ORAL | CAPSULE | 765.00 mg | Correction | ||
| Q2 2024 | GLYCERYL MONO- AND DICAPRYLOCAPRATE | ORAL | CAPSULE | 13770mg | Correction | ||
| Q1 2024 | GLYCERYL MONO AND DICAPRYLOCAPRATE | ORAL | CAPSULE, DELAYED RELEASE | 24mg | Correction | ||
| Q2 2024 | GLYCERYL MONO- AND DICAPRYLOCAPRATE | ORAL | CAPSULE, DELAYED RELEASE | 24mg | Correction | ||
| Q1 2024 | GLYCERYL MONO AND DICAPRYLOCAPRATE | ORAL | CAPSULE, GELATIN COATED | 62.20 mg | Correction | ||
| Q2 2024 | GLYCERYL MONO- AND DICAPRYLOCAPRATE | ORAL | CAPSULE, GELATIN COATED | 62.20 mg | Correction | ||
| Q1 2024 | GLYCERYL MONO AND DICAPRYLOCAPRATE | ORAL | CAPSULE, LIQUID FILLED | 139.00 mg | Correction | ||
| Q2 2024 | GLYCERYL MONO- AND DICAPRYLOCAPRATE | ORAL | CAPSULE, LIQUID FILLED | 139mg | Correction | ||
| Q1 2024 | GLYCERYL MONO AND DICAPRYLOCAPRATE | ORAL | SOLUTION | 30.00 mg/ 1.00 ml | Correction | ||
| Q2 2024 | GLYCERYL MONO- AND DICAPRYLOCAPRATE | ORAL | SOLUTION | 300mg | Correction | ||
| Q1 2024 | GLYCERYL MONO AND DICAPRYLOCAPRATE | ORAL | TABLET | 1.30 mg | Correction | ||
| Q2 2024 | GLYCERYL MONO- AND DICAPRYLOCAPRATE | ORAL | TABLET | 1.30 mg | Correction | ||
| Q1 2024 | GLYCERYL MONO AND DIPALMITOSTEARATE | ORAL | CAPSULE | 16mg | Correction | ||
| Q2 2024 | GLYCERYL MONO- AND DIPALMITOSTEARATE | ORAL | CAPSULE | 16mg | Correction | ||
| Q1 2024 | GLYCERYL MONO AND DIPALMITOSTEARATE | ORAL | CAPSULE, DELAYED RELEASE | 25mg | Correction | ||
| Q2 2024 | GLYCERYL MONO- AND DIPALMITOSTEARATE | ORAL | CAPSULE, DELAYED RELEASE | 25mg | Correction | ||
| Q1 2024 | GLYCERYL MONO AND DIPALMITOSTEARATE | ORAL | TABLET, DELAYED RELEASE | 3mg | Correction | ||
| Q2 2024 | GLYCERYL MONO- AND DIPALMITOSTEARATE | ORAL | TABLET, DELAYED RELEASE | 3mg | Correction | ||
| Q1 2024 | GLYCERYL MONO AND DIPALMITOSTEARATE | ORAL | TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE | 28mg | Correction | ||
| Q2 2024 | GLYCERYL MONO- AND DIPALMITOSTEARATE | ORAL | TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE | 28mg | Correction | ||
| Q1 2024 | GLYCERYL MONO AND DIPALMITOSTEARATE | TOPICAL | CREAM | 312mg | Correction | ||
| Q2 2024 | GLYCERYL MONO- AND DIPALMITOSTEARATE | TOPICAL | CREAM | 312mg | Correction | ||
| Q1 2024 | GLYCERYL MONO AND DIPALMITOSTEARATE | VAGINAL | CREAM | 160mg | Correction | ||
| Q2 2024 | GLYCERYL MONO- AND DIPALMITOSTEARATE | VAGINAL | CREAM | 160mg | Correction | ||
| Q1 2024 | GLYCERYL MONO AND DICAPRYLOCAPRATE | ORAL | CAPSULE | 765.00 mg | MDE Replacement | ||
| Q2 2024 | GLYCERYL MONO- AND DICAPRYLOCAPRATE | ORAL | CAPSULE | 13770mg | MDE Replacement | ||
| Q1 2024 | GLYCERYL MONO AND DICAPRYLOCAPRATE | ORAL | CAPSULE, LIQUID FILLED | 139.00 mg | MDE Replacement | ||
| Q2 2024 | GLYCERYL MONO- AND DICAPRYLOCAPRATE | ORAL | CAPSULE, LIQUID FILLED | 139mg | MDE Replacement | ||
| Q1 2024 | GLYCERYL MONO AND DICAPRYLOCAPRATE | ORAL | SOLUTION | 30.00 mg/ 1.00 ml | MDE Replacement | ||
| Q2 2024 | GLYCERYL MONO- AND DICAPRYLOCAPRATE | ORAL | SOLUTION | 300mg | MDE Replacement |
FDA/Center for Drug Evaluation and Research
Office of Pharmaceutical Quality
Office of Policy for Pharmaceutical Quality
Mailbox for IID corrections: IIDUpdate@fda.hhs.gov
Update Frequency: Quarterly
Data Through: March 15, 2024
Database Last Updated: April 29, 2024